Lanean...

Adverse Events of Trastuzumab Emtansine (T-DM1) in the Treatment of HER2-Positive Breast Cancer Patients

The human epidermal growth factor receptor 2 (HER2) is commonly associated with poor prognosis and is overexpressed in approximately 15–20% of all breast cancers. The introduction of HER2-targeted therapies led to significant improvement in the prognosis of patients with HER2-positive breast cancer,...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Breast Care (Basel)
Egile Nagusiak: Kowalczyk, Lidia, Bartsch, Rupert, Singer, Christian F., Farr, Alex
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: S. Karger GmbH 2017
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5803744/
https://ncbi.nlm.nih.gov/pubmed/29456473
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000480492
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!